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METHODS
INTRODUCTION AND PURPOSE RESULTS
Candida species are among the top 10 most frequently isolated
nosocomial bloodstream pathogens in Europe. In particular, in
neonatal intensive care units (NICUs) Candida infections are an
emerging concern because of the increasing incidence, the related
high morbidity and mortality rates reported. Moreover, the
epidemiology of Candida infection rapidly changed in these years
leading to the selection of less sensitive strains and species.
Surveillance studies are mandatory to identify the local distribution of
species, their antifungal susceptibility profiles and the emergence of
resistance strains.
From December 2012 to June 2016 we enrolled 874 neonates and analyzed
respectively 2014 nasal and rectal swabs. 20/2014 (0,99%) of nasal swabs and
128/2014 (6,35%) of rectal swabs tested positive for Candida spp. The species
distribution is showed in the Graph 1. 89/874 (10,18%) neonates tested positive at
least in one swab. 59 isolates of NCAC species were tested with the main antifungal
agents. All the tested strains were susceptible to echinocandins and amphotericin B.
The susceptibility patterns for azoles are shown in the Table 1.
From December 2012 we performed a cohort prospective surveillance
study on Candida colonization in our NICU, collecting weekly nasal and
rectal swabs. Swabs were placed on Sabouraud agar. Candida growth
on agar plates was confirmed by microscopic observation.
Furthermore, Candida spp. was identified through Candida
chromogenic agar (Candida chromogenic agar, Laboratorios Conda)
and API® 20C AUX (Biomérieux). The first isolated non-C.albicans
Candida (NCAC) species from colonized patients were tested with the
main antifungal agents (YeastOne® Y010 Thermo Fisher Scientific)
and the obtained MIC values were read according to CLSI..
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CONCLUSIONS
Our study confirm the rule of surveillance in the prevention and control of Candida spp. healthcare related infections especially in an high risk ward such as NICU.
In particular, in our NICU fluconazole prophylaxis is administered according to standard protocols from 2009. Antifungal susceptibility testes allowed to identify
resistant and mutant strains whom acquired resistance so to obtain both clinical and epidemiological data promptly.
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Graph 1: Species distribution in nasal and rectal swabs
C.gulliermondii
C.famata
C.glabrata
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Table 1: Azoles susceptibility patterns
Candida (C.) 
species
PZ
VOR IZ FZ
N°
isolates
MIC
CBPs ECVs
MIC
CBPs ECVs
MIC
CBPs ECVs
MIC
CBPs ECVs
C.famata ≤0,008 S N.I. 0,03 S N.I. 0,03 S N.I. 2 S N.I. 3/3 
C.glabrata 
1 N.I. WT 1 S WT 0,5 DDS WT 32 DDS WT 5/11
0,25 N.I. WT 0,25 S WT 0,12 S WT 16 DDS WT 1/11 
1 N.I. WT 1 S WT 2 R WT 32 DDS WT 4/11 
>8 N.I. noWT >8 R noWT >16 R noWT 258 R noWT 1/11 
C. guilliermondii
≤0,008 S N.I. 0,06 S WT ≤0,015 S N.I. 4 S WT 1/4 
0,25 N.I. N.I. 0,5 S noWT 0,5 DDS N.I. 16 DDS noWT 1/4 
0,5 N.I. N.I. 2 DDS noWT 1 R N.I. 64 R noWT 1/4 
1 N.I. N.I. 4 DDS noWT 8 R N.I. 64 R noWT 1/4 
C.parapsilosis
0,015 N.I. WT 0,06 S WT 0,03 S WT 2 S WT 30/41
≤0,008 S WT 0,06 S WT ≤0,015 S WT 4 DDS noWT 6/41 
0,015 N.I. WT 0,06 S WT 0,03 S WT 64 R noWT 2/41 
0,5 N.I. WT 0,5 S noWT 0,5 DDS noWT 16 R noWT 1/41 
2
N.I. noWT
>1
R noWT
>1
R noWT
>32
R noWT 2/41
PZ=posaconazole, VOR=voriconazole, IZ=itraconazole, FZ= fluconazole, CBPs= clnical break-points, ECVs= epidemiological
cutoff values
N.I.= no interpretation available, S= susceptible, DDS= dose dipendent suscestible, R= resistant, WT= wild type, noWT=no 
wild type
